>Which company will develop a new, novel, first in class HCV and HBV treatment, which can also be a prophylaxis, and maybe also a vaccine?<
The way you phrased the question, the answer is nobody.
The HBV and HCV viruses have sufficiently little in common that a compound with direct antiviral activity against one of them is unlikely to have direct antiviral activity against the other.
Market Data 
Markets 
AI
